Egene Inc (fka EGEI)

[ProfitScout]

eGene Profiled in Prestigious 'Genetic Engineering News' Magazine

IRVINE, Calif., May 12, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading biotechnology company that has developed a compact and automated digital genetic analyzer, is the focus of a corporate profile in the prestigious "Genetic Engineering News" magazine's May 15 issue.

"Genetic Engineering News" is the most widely read biotechnology publication around the globe, read by biotechnology executives and investors worldwide. The article can be found at: http://www.genengnews.com/current/article.aspx?id=1620.

In the May 15 issue, writer Carol Potera describes eGene as a company that "transforms the genetic analysis field." The story states: "Just as email and eBay changed the way people think about communications and retailing, the name eGene represents a paradigm shift in the way that scientists think about genetic analysis." The story notes that Dr. Ming Liu, acting CEO of eGene, notes that "the automatic, affordable, user-friendly capillary electrophoresis genotyping system, offered by eGene, represents the future of DNA analysis."

The HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. eGene recently announced that it can successfully identify the DNA of the bird flu virus through RT-PCR method in as little as six minutes for 12 samples or 50 minutes for 96 samples.

eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.

Martin E. Janis & Co. Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]


Copyright Business Wire 2006